Upsher-Smith to Present Innovative Rare Disease Solutions at AAN 2025
Upsher-Smith to Present Innovative Rare Disease Solutions at AAN 2025
Upsher-Smith Laboratories, LLC is set to participate in the prestigious 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5-9 in beautiful San Diego, California. This event will be a significant platform for Upsher-Smith to showcase its expanding portfolio of treatments aimed at rare diseases, particularly focusing on innovative new products designed to support affected patients and healthcare providers.
Highlighting VIGAFYDE™ – A Game-Changer for Infantile Spasms
One of the key highlights at the Upsher-Smith booth (#846) will be the introduction of VIGAFYDE™ (vigabatrin) Oral Solution, a groundbreaking ready-to-use liquid medication aimed at treating infantile spasms (IS) in infants aged between one month to two years. This product is the first of its kind and represents a significant advancement in treating this challenging condition which often poses serious risks of developmental delays and other complications associated with seizures.
VIGAFYDE™ is formulated for use as a monotherapy and is available under stringent guidelines to balance its benefits against the risk of potential vision loss, a critical consideration for both clinicians and families. "With the launch of VIGAFYDE™, we aim to simplify the treatment regimen for infantile spasms, ensuring that patients and healthcare providers can effortlessly manage dosage and administration," stated Jim Maahs, Upsher-Smith's Head of Commercial.
Expanding Treatment Options in Rare Diseases
Since entering the specialty pharmacy landscape in 2018 with the launch of VIGADRONE® (vigabatrin) Powder for Oral Solution, Upsher-Smith has consistently worked to expand its offerings to better serve patients with rare neurological conditions. Their product range now includes multiple forms of vigabatrin, including the recently launched VIGAFYDE™, along with VIGADRONE® Tablets and TORPENZ™ (everolimus) Tablets.
TORPENZ™, unique in its ability to manage certain manifestations of Tuberous Sclerosis Complex (TSC), will also be showcased during the meeting. This treatment has been pivotal for patients dealing with renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA), offering hope for those in need of alternatives.
Commitment to Comprehensive Support Through the Promise of Support™ Program
Central to Upsher-Smith's philosophy is its Promise of Support™ Program, which provides comprehensive resources and support for patients, caregivers, and healthcare providers throughout their treatment journey. The program has facilitated easy access to medications, education materials, and financial assistance to help alleviate the burdens often faced by those in the rare disease community.
Not Just Medications – Prioritizing Patient Education
With both VIGAFYDE™ and its Promise of Support™ Program, Upsher-Smith emphasizes education. Healthcare providers can expect to find resources detailing safe usage, potential risks, and tips for monitoring patients effectively. Regular vision testing is advocated for all patients receiving vigabatrin to manage risks effectively, and the program stands ready to assist with navigating insurance and prior authorization hurdles that can complicate access to care.
At the AAN meeting, clinicians and healthcare practitioners will have the opportunity to engage directly with Upsher-Smith representatives to better understand these innovative resources and how they can facilitate improved patient outcomes in rare disease treatment.
Looking Forward To A New Era in Rare Disease Management
In conclusion, Upsher-Smith's participation at this year's AAN Annual Meeting represents not merely a showcase of their products but a commitment to fostering a brighter future for rare disease management. As they transition into an era defined by innovation and patient-first solutions, their efforts symbolize hope for countless families navigating the complexities of medical treatment.
To learn more about Upsher-Smith, their extensive portfolio, and the Promise of Support™ Program, please visit Upsher-Smith's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.